A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy

BACKGROUND: CD19 chimeric antigen receptor (CAR) therapy has achieved impressive success in relapsed or refractory (R/R) B-cell malignancies, but relapse due to antigen escape is increasingly appearing reported. As the expression profile of CD22 is similar to that of CD19, CD22 has become a candidat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yu, Li, Saisai, Wang, Ying, Lu, Yang, Xu, Yingxi, Rao, Qing, Wang, Huijun, Xing, Haiyan, Tian, Zheng, Tang, Kejing, Lv, Lulu, Wang, Min, Wang, Jianxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939233/
https://www.ncbi.nlm.nih.gov/pubmed/35317863
http://dx.doi.org/10.1186/s40164-022-00270-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939233/
https://www.ncbi.nlm.nih.gov/pubmed/35317863
http://dx.doi.org/10.1186/s40164-022-00270-5

Ejemplares similares